Cytotoxic activity of compounds against HePG2, HCT-116, and MCF-7 tumor cell lines.

In vitro cytotoxicity IC50 (μM)
Compound No	Substitution			HePG2	HCT-116	MCF-7	Compound no	Substitution			HePG2	HCT-116	MCF-7
	n	R	R1					n	R	R1
DOXa	—	—	—	4.50 ± 0.2	5.23 ± 0.3	4.17 ± 0.2	6i	1	Br	F	20.44 ± 1.5	14.27 ± 1.1	25.32 ± 2.0
6a	1	H	F	85.14 ± 4.1	>100	93.55 ± 4.7	6j	2	H	H	34.13 ± 1.9	22.09 ± 1.6	31.26 ± 2.3
6b	1	CH3	F	55.38 ± 3.2	66.33 ± 3.1	58.11 ± 3.3	6k	2	H	F	78.24 ± 3.8	83.65 ± 4.0	80.62 ± 4.1
6c	1	F	H	49.08 ± 2.9	47.87 ± 2.6	54.65 ± 3.1	6l	2	CH3	H	61.62 ± 3.5	57.51 ± 3.1	63.22 ± 3.5
6d	1	F	F	7.97 ± 0.5	9.49 ± 0.6	13.87 ± 0.9	6m	2	CH 3	F	11.97 ± 0.8	28.37 ± 1.9	19.87 ± 1.4
6e	1	OCH3	H	45.38 ± 2.5	38.14 ± 2.4	42.71 ± 2.5	6n	2	F	H	65.44 ± 3.7	71.27 ± 3.5	75.84 ± 3.9
6f	1	OCH3	F	88.31 ± 4.3	>100	>100	6o	2	F	F	6.02 ± 0.3	5.84 ± 0.2	8.89 ± 0.5
6g	1	Cl	F	52.04 ± 2.8	60.19 ± 3.3	69.44 ± 3.7	6p	2	OCH3	H	73.33 ± 3.9	79.63 ± 3.7	86.89 ± 4.3
6h	1	Br	H	91.36 ± 4.8	>100	>100	6q	2	OCH3	F	41.20 ± 2.3	32.19 ± 2.2	37.44 ± 2.6

^aDOX: Doxorubicin.